Advancing science and policy to reduce health risks where people live, work and play

A B C D E F G H J K L M N O P R S T U W X Y Z

Tamara Minko Ph.D.

Distinguished Professor – Chair, Department of Pharmaceutics Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Work William Levine Hall Room 214 160 Frelinghuysen Road Piscataway NJ 08854 Work Phone: 848-445-0145 Work Fax: 732-445-3134
Photo of Tamara Minko Ph.D.

Biographical Info

Dr. Tamara Minko is a Professor II and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. She is also a member of the Cancer Institute of New Jersey, Environmental and Occupational Health Sciences Institute. Her current research interests include drug delivery; biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Professor Minko is author and co-author of more than 400 publications (peer-reviewed papers, books and textbook chapters, conference proceedings, patents). Many of her papers are well cited and published in prestigious journals with high impact factors including PNAS, Nature Nanotechnology, Cancer Research, Clinical Cancer Research, Advanced Drug Delivery Review, Journal of Controlled Release, etc. Dr. Minko is a Fellow of the American Association of Pharmaceutical Scientists, elected member of the Board of Scientific Advisors of the Controlled Release Society, recipient of numerous awards, Editor of Pharmaceutical Research, member of editorial board of several scientific journals and a member of Study Sections at NIH, DOD, American Heart Association and other national and international review panels. Her research is supported by grants from NIH, NSF, DOD and other national and international sources.

Research Areas

Biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia.

Ongoing/Recent Research Support

  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 04/01/03 – 07/31/12. NIH/NCI R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular Targeting of Drug Delivery System to Cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination Nanotherapeutic Strategies to Overcome Tumor Drug Resistance.
  • 07/01/09 – 06/30/12. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • Ongoing Research Support:
  • 07/01/10 – 05/31/15. NIH/NCI R01CA138533, T. Minko – Principal Investigator. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging.
  • 10/01/09 – 09/31/11. NIH/NCI (ARRA) R01 CA100098, T. Minko – Principal Investigator, Targeted Proapoptotic Anticancer Drug Delivery System.
  • 04/07/06 – 02/28/12. NIH/NCI R01 CA111766, T. Minko – Principal Investigator. Molecular targeting of drug delivery system to cancer.
  • 09/01/10 – 07/31/15. U54CA151881, T. Minko – Principal Investigator, Combination nanotherapeutic strategies to overcome tumor drug resistance.
  • 07/01/09 – 06/30/11. NIH/NIBIB R01 EB008278, T. Minko – Co-Investigator. Efficient Cellular Delivery of Oligonucleotides. (Principal Investigator – Dr. C. M. Roth, Department of Chemical & Biochemical Engineering, Rutgers University).
  • 09/15/06 – 06/30/11. NIH/NIBIB R01 EB007049, T. Minko – Co- Principal Investigator. Carrier Shape Matters: Filomicelles, Long-circulation, and the EPR effect. (Principal Investigator – Dr. D. Discher, University of Pennsylvania).
  • 12/01/09 – 11/30/12. National Science Foundation CBET 0933966, T. Minko – Co-Principal Investigator. Novel Self Assembly of siRNA for Efficient and Safe Delivery. (Principal Investigator – Dr. H. He, Department of Chemistry, Newark, Rutgers University).
  • 07/01/10 – 06/30/11. Department of Defense Lung Cancer Research Program W81XWH-10-1-0347, T. Minko Co-Investigator (Principal Investigator – Dr. O. Taratula, Postdoctoral Research Associate working under the supervision of Dr. Minko). Innovative Strategy for Treatment of Lung Cancer: Inhalatory Co-Delivery of Anticancer drugs and siRNA for Suppression of Cellular Resistance.

Research Highlights

  • Nanotechnology based inhalatory treatment of lung cancer
  • Targeted multifunctional approach for treatment of multidrug resistant cancer and prevention of metastases
  • Prevention of cellular hypoxic damage by the suppression of Jun N-Terminal Kinase 1

Scholarly Activities

  • 2010 Member (Elected), Board of Scientific Advisors, Controlled Release Society
  • 2009 Fellow of the American Association of Pharmaceutical Scientists (AAPS)
  • 2008, 2010, 2011 Controlled Release Society Outstanding Pharmaceutical Paper Award
  • 1998 The Jorge Heller Journal of Controlled Release/Controlled Release Society Outstanding Paper Award

Recent Publications

  1. Rather, GM, Anyanwu, M, Minko, T, Garbuzenko, O, Szekely, Z, Bertino, JR. Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin. Cancers (Basel). 2021;13 (5):. doi: 10.3390/cancers13050972. PubMed PMID:33652640 PubMed Central PMC7956530
  2. Allenspach, C, Timmins, P, Lumay, G, Holman, J, Minko, T. Loss-in-weight feeding, powder flow and electrostatic evaluation for direct compression hydroxypropyl methylcellulose (HPMC) to support continuous manufacturing. Int J Pharm. 2021;596 :120259. doi: 10.1016/j.ijpharm.2021.120259. PubMed PMID:33486020
  3. Majumder, J, Minko, T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23 (1):14. doi: 10.1208/s12248-020-00532-2. PubMed PMID:33400058 PubMed Central PMC7784226
  4. Majumder, J, Minko, T. Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Adv Ther (Weinh). 2020; :2000203. doi: 10.1002/adtp.202000203. PubMed PMID:33173809 PubMed Central PMC7646027
  5. Skupin-Mrugalska, P, Minko, T. Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation-Positive Lung Cancer Cells. Pharmaceutics. 2020;12 (10):. doi: 10.3390/pharmaceutics12100939. PubMed PMID:33008019 PubMed Central PMC7599969
  6. Majumder, J, Minko, T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18 (2):205-227. doi: 10.1080/17425247.2021.1828339. PubMed PMID:32969740 PubMed Central PMC7904578
  7. Minko, T. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the ‘Undruggable’ MYC in Pancreatic Cancer. Trends Pharmacol Sci. 2020;41 (10):684-686. doi: 10.1016/j.tips.2020.08.008. PubMed PMID:32893006
  8. Shen, AM, Minko, T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326 :222-244. doi: 10.1016/j.jconrel.2020.07.011. PubMed PMID:32681948 PubMed Central PMC7501141
  9. Allenspach, C, Timmins, P, Sharif, S, Minko, T. Characterization of a novel hydroxypropyl methylcellulose (HPMC) direct compression grade excipient for pharmaceutical tablets. Int J Pharm. 2020;583 :119343. doi: 10.1016/j.ijpharm.2020.119343. PubMed PMID:32305364
  10. Garbuzenko, OB, Kuzmov, A, Taratula, O, Pine, SR, Minko, T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 2019;9 (26):8362-8376. doi: 10.7150/thno.39816. PubMed PMID:31754402 PubMed Central PMC6857061
Search PubMed
Categories: Faculty, Toxicology, Member, Tox Member
Updated 2 months ago.

170 Frelinghuysen Road, Piscataway, NJ 08854 – 848-445-0200  Fax: 732-445-0131

Copyright © 2021, Rutgers, The State University of New Jersey